Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
F Boscia, D Veritti, C Iaculli… - European Journal …, 2024 - journals.sagepub.com
The high prevalence of Diabetic macular edema (DME) is a real global health problem. Its
complex pathophysiology involves different pathways. Over the last decade, the introduction …
complex pathophysiology involves different pathways. Over the last decade, the introduction …
Characterization of Receptor Binding Affinity for Vascular Endothelial Growth Factor with Interferometric Imaging Sensor
Wet Age-related macular degeneration (AMD) is the leading cause of vision loss in
industrialized nations, often resulting in blindness. Biologics, therapeutic agents derived …
industrialized nations, often resulting in blindness. Biologics, therapeutic agents derived …
Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach
M Blanot, RP Casaroli-Marano… - International Journal of …, 2024 - mdpi.com
Intravitreal aflibercept injection (IAI) is a treatment for diabetic macular edema (DME), but its
mechanism of action (MoA) has not been completely elucidated. Here, we aimed to explore …
mechanism of action (MoA) has not been completely elucidated. Here, we aimed to explore …
Aflibercept for Diabetic Macular Edema in Real-Life Practice in GREece: Three-Year Outcomes of the ADMIRE Study
I Chatziralli, C Agapitou, E Dimitriou… - Seminars in …, 2024 - Taylor & Francis
Purpose To evaluate the efficacy and safety of intravitreal aflibercept injections for diabetic
macular edema (DME) treatment in a tertiary referral center in Greece. Methods ADMIRE …
macular edema (DME) treatment in a tertiary referral center in Greece. Methods ADMIRE …
Factors influencing response to Aflibercept in diabetic macular oedema patients in a diverse North West London population: a real-world study
SY Sim, A Ghulakhszian, A Minocha… - Clinical …, 2021 - Taylor & Francis
Background Diabetic macular oedema (DMO) is the leading cause of sight impairment in
working age populations in developed countries. Current first line treatment for centre …
working age populations in developed countries. Current first line treatment for centre …
Correction: Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
C Dinah, A Ghulakhszian, SY Sim, A Minocha… - Plos one, 2021 - journals.plos.org
1. Dinah C, Ghulakhszian A, Sim SY, Minocha A, Nokhostin S, Posner E, et al.(2021)
Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real …
Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real …
Vergleich der Compliance von Patienten mit diabetischem Makulaödem und Patienten mit Makulaödem infolge einer altersbedingten Makuladegeneration bei …
MNJ Weiß - 2022 - edoc.ub.uni-muenchen.de
Sowohl die altersbedingte Makuladegeneration (AMD) als auch das diabetische
Makulaödem (DMÖ) sind Hauptursachen für Erblindungen in der westlichen Welt. Aufgrund …
Makulaödem (DMÖ) sind Hauptursachen für Erblindungen in der westlichen Welt. Aufgrund …
[HTML][HTML] Diabetic macular oedema treated with Aflibercept
S London, N London, E London - thelondonpress.uk
Background Diabetic macular oedema (DMO) is a number one explanation for sight
impairment within the working age inhabitants with roughly 21 million people affected …
impairment within the working age inhabitants with roughly 21 million people affected …